Table S1. Clinical and laboratory data of the CLL patients studied.

Individual Nr.	1	2	3	4
PB lymphocytes (% of leukocytes)	98	99	98	94
Prior treatment	no	yes	yes	no
SF3B1 variant frequency* (%)	45	52	0	0
SF3B1 CDS variant	c.2098A>G	c.2098A>G	none	none
SF3B1 AA variant	p.K700E	p.K700E	none	none
TP53 variant frequency (%)	30	44; 12	32; 25	80
TP53 CDS variant	c.808T>C	c.702_710delCAACTACAT; c.742C>T	c.617T>A; c.695_719del25	c.712T>G
TP53 AA variant	p.F270L	p.Y234*; p.R248W	p.L206*; p.I232fs*6	p.C238G
BRAF variant frequency (%)	0	49	0	0
BRAF CDS variant	none	c.1406G>C	none	none
BRAF AA variant	none	p.G469A	none	none
NOTCH1 variant frequency (%)	0	0	50	0
NOTCH1 CDS variant	none	none	c.7544_7545delCT	none
NOTCH1 AA variant	none	none	p.P2515fs*4	none

*Variant frequencies as determined by 454 sequencing are provided.
PB = peripheral blood, CDS = coding sequence, AA = amino acid.